BLK
47
3
GS
65
16
PPL
44
9
NWSA
69
4
PM
49
8
USB
50
3
KIM
58
2
DLTR
52
8
LEG
16
2
PBI
30
-8
UNH
42
6
PH
60
5
LH
33
3
NWL
48
4
LUV
45
3
PYPL
49
4
JNJ
30
4
CHD
34
7
HPQ
55
3
UAL
73
3
BLK
47
3
GS
65
16
PPL
44
9
NWSA
69
4
PM
49
8
USB
50
3
KIM
58
2
DLTR
52
8
LEG
16
2
PBI
30
-8
UNH
42
6
PH
60
5
LH
33
3
NWL
48
4
LUV
45
3
PYPL
49
4
JNJ
30
4
CHD
34
7
HPQ
55
3
UAL
73
3
Financhill
Back

Cidara Therapeutics Stock Predictions

These 7 Stocks Will Be Magnificent in 2025

Get Your Copy of "These 7 Stocks Will Be Magnificent in 2025" Here.
Buy
61

CDTX
Cidara Therapeutics

Last Price:
$23.26
Seasonality Move:
12.86%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump's Legacy-Defining Momentor Strike

But the Surprising Way Trump Solves it Could Cement His Legacy.

Cidara Therapeutics Stock Forecast

  • Over the next 52 weeks, Cidara Therapeutics has on average historically fallen by 16% based on the past 9 years of stock performance.
  • Cidara Therapeutics has fallen lower in 7 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 77.78%
  • Is Cidara Therapeutics Stock Undervalued?
    The current Cidara Therapeutics [CDTX] share price is $23.22. The Score for CDTX is 61, which is 22% above its historic median score of 50, and infers lower risk than normal.
  • CDTX is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.

Will Cidara Therapeutics Stock Go Up Next Year?

  • Over the next 52 weeks, Cidara Therapeutics has on average historically fallen by 16% based on the past 9 years of stock performance.

Cidara Therapeutics Stock Rating

Buy
61
Cidara Therapeutics (CDTX) is a Buy

Is Cidara Therapeutics overpriced?

  • Cidara Therapeutics has fallen lower in 7 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 77.78%

Cidara Therapeutics Stock Price History

Is CDTX stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CDTX is experiencing slight buying pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
cidara.com

52-Week Data

52-Week High:
24.99
52-Week Low:
10.00

Prediction Charts

Market Cap:
254M
Price in USD:
23.22
Volume:
148.4K
Beta:
1.44

Technical Analysis

SMA50:
16.16
SMA100:
13.95
SMA200:
13.73
52-Wk Change:
54.8%

Stock Predictions

  • Is Cidara Therapeutics stock public?
    Yes, Cidara Therapeutics is a publicly traded company.
  • What is the Cidara Therapeutics stock quote today?
    The Cidara Therapeutics stock price is 23.22 USD today.
  • How to buy Cidara Therapeutics stock online?
    You can buy Cidara Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Dec-3 18.80 17.71 18.96 17.41
Dec-4 17.95 19.95 20.33 17.83
Dec-5 19.84 19.93 20.66 18.03
Dec-6 19.27 23.73 24.00 18.43
Dec-9 23.51 22.51 24.00 22.14
Dec-10 22.17 22.17 24.00 22.15
Dec-11 21.94 21.82 22.25 21.22
Dec-12 21.48 21.64 22.08 21.15
Dec-13 22.78 22.88 23.89 22.20
Dec-16 22.83 23.26 23.66 22.80
Dec-17 23.17 22.81 24.99 22.10
Dec-18 22.47 20.53 22.78 19.24
Dec-19 20.49 22.51 23.21 20.24
Dec-20 22.12 23.22 24.00 21.20

Cidara Therapeutics Earnings

Cidara Therapeutics Earnings Report: Per Share Cidara Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.

Cidara Therapeutics Forecast Revenue Growth

Cidara Therapeutics Stock Analysis: Historical quarterly revenues per share for Cidara Therapeutics and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $2.22 per share, a decrease next quarter of $0.00 per share, a decrease this year of $16.29 per share, and an increase next year of $13.86 per share.

* Cidara Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.